| |NOVEMBER 20238Shanghai Henlius Biotech, Inc. reported exploratory new drug applications for the novel EGFR-targeted antibody-drug conjugate (ADC) HLX42 and the novel PD-L1-targeted ADC for injection HLX43. By the National Medical Products Administration (NMPA) for the treatment of advanced/metastatic solid tumors.The company developed these two products in collaboration with MediLink Therapeutics and are the first Henlius ADC candidates to enter clinical development. Considering that there are few ADC candidates targeting PD-L1, HLX43 is the first ADC targeting PD-L1 in China. In addition, Henlius has several other ADC/AXC candidates in preclinical development in its portfolio.EGFR belongs to the family of receptor tyrosine kinases and plays an important role in maintaining normal cell functions such as cell proliferation, differentiation and migration. EGFR mutation or over expression is considered to be closely related to the occurrence of various solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), etc. Studies have shown that targeting EGFR is a viable strategy for anticancer therapy.Despite the great success of monoclonal antibodies targeting EGFR and 3rd generation EGFR tyrosine kinase inhibitors (TKIs), there remains a large unmet medical need for effective therapies for patients who do not respond to current therapies or who relapse after conventional therapy. ADC technology has developed tremendously in recent years and offers a new treatment option for tumor patients. EGFR-targeted ADC can overcome resistance to EGFR monoclonal antibodies and EGFR TKIs, which may bring clinical benefit to more patients with advanced NSCLC/CRC resistant or resistant to conventional EGFR-targeted therapy. POAccording to Grant Thornton Bharat Pharma and Healthcare Dealtracker, deals in India's healthcare and pharmaceutical sector grew by 298 percent in July-September 2023 compared to the same quarter last year.According to the report, the number of transactions in India decreased by 32 percent in the July-September period of 2023. The largest deal during that period was the purchase of Nirman from Glenmark Lifesciences for $689 million. Another deal worth more than $100 million was the acquisition of AMRI Hospitals Ltd to Manipal Health Enterprises Ltd for $280 million.API and CDMO of life sciences and individual health specialties have emerged as focus areas in which investor interest has grown. During the quarter, 26 deals were completed with a total value of $2.7 billion. Compared to the April-June quarter, this is a 26 percent decrease and a 14 percent decrease in the value of contracts."While healthcare deal volumes may remain muted, industry growth drivers such as growing healthcare demand , technology adoption and government support are likely to continue," said Bhanu Prakash Kalmath, partner and head of healthcare at Grant Thornton Bharat.Trade volumes in the cross-border region have decreased. In the quarter under review, there was only one deal in the entry-level segment when Gleneagles Development acquired Ravindranath GE Medical Associates for $90 million.The PE landscape marked its lowest quarterly volume in three years with 18 deals totaling $1.4 billion. Despite contract values and volumes decreasing this quarter compared to the previous quarter, values increased significantly compared to July-September 2022 by 147 percent. POCHINA NMPA APPROVES DRUGS FOR TREATMENT SOLID TUMOURSINDIAN PHARMA HEALTHCARE DEALS VALUE JUMPS 298 PERCENTTOP STORIESChina NMPA Approves Drugs for Treatment Solid Tumours
< Page 7 | Page 9 >